Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib

Shirley Abraham; Mohamed Salama; Jeffrey Hancock; Jeffrey Jacobsen; Mark Fluchel

doi:10.1002/pbc.24148

Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib

Shirley Abraham, Mohamed Salama, Jeffrey Hancock, Jeffrey Jacobsen, Mark Fluchel

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.

Original language	English (US)
Pages (from-to)	928-929
Number of pages	2
Journal	Pediatric Blood and Cancer
Volume	59
Issue number	5
DOIs	https://doi.org/10.1002/pbc.24148
State	Published - Nov 2012

Keywords

Imatinib
Myeloproliferative disorders
PGFRB

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.24148

Cite this

@article{46f81461630944faa7fea0a48357d4d4,

title = "Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib",

abstract = "Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.",

keywords = "Imatinib, Myeloproliferative disorders, PGFRB",

author = "Shirley Abraham and Mohamed Salama and Jeffrey Hancock and Jeffrey Jacobsen and Mark Fluchel",

year = "2012",

month = nov,

doi = "10.1002/pbc.24148",

language = "English (US)",

volume = "59",

pages = "928--929",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "5",

}

TY - JOUR

T1 - Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib

AU - Abraham, Shirley

AU - Salama, Mohamed

AU - Hancock, Jeffrey

AU - Jacobsen, Jeffrey

AU - Fluchel, Mark

PY - 2012/11

Y1 - 2012/11

N2 - Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.

AB - Eosinophilia is seen in several myeloproliferative disorders (MPD). A subset of MPD involves the platelet-derived growth factor receptor beta (PDGFRB) gene. Imatinib mesylate has been efficacious in treating some of these MPDs. Here we describe two patients with MPD with eosinophilia and PDGFRB rearrangements, one of which was congenital. Both patients were treated with single agent imatinib and continue to be in clinical, hematologic, and cytogenetic remission despite weaning doses. No definite guidelines currently exist regarding the exact dosing and duration of imatinib therapy for these patients.

KW - Imatinib

KW - Myeloproliferative disorders

KW - PGFRB

UR - http://www.scopus.com/inward/record.url?scp=84866180874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866180874&partnerID=8YFLogxK

U2 - 10.1002/pbc.24148

DO - 10.1002/pbc.24148

M3 - Article

C2 - 22488677

AN - SCOPUS:84866180874

SN - 1545-5009

VL - 59

SP - 928

EP - 929

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

ER -

Congenital and Childhood myeloproliferative disorders with eosinophilia responsive to imatinib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this